greeksoup/ stock research
Stock research / United States / RDY / Year to 31 March 2024

Dr. Reddy’s Laboratories Limited (RDY) annual results, year to 31 March 2024: revenue INR 279,164 million, from the 20-F

Dr. Reddy’s Laboratories Limited files a 20-F with the SEC once a year, in Indian rupees. In the year to 31 March 2024 it reported revenue of INR 279,164 million ($3.4 billion at the year's average rate), up 13.5% on the year before. Its profit attributable to shareholders was INR 55,684 million, up 23.6%, and diluted earnings per share INR 66.80.

Revenue
INR 279,164 million
+13.5% on the year
FY2017FY2024
Operating margin
24.3%
23.2% a year earlier
FY2017FY2024
Net income
INR 55,684 million
+23.6% on the year
FY2017FY2024
Diluted EPS
INR 66.80
+23.3% on the year
FY2017FY2024

this yearthe year beforeIn Indian rupees as filed. Hover a bar for its figure.

Income statement (profit and loss)

Year toMar 2023Mar 2024
Revenue245,879279,164
Cost of sales106,536115,557
Gross profit139,343163,607
Research and development19,38122,873
Selling, general and administrative68,02677,201
Operating profit57,14467,729
Finance costs1,4281,711
Profit before tax60,36771,870
Income tax15,30016,186
Profit for the year45,06755,684
Profit attributable to shareholders45,06755,684
Filing20-F20-F
INR million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed.
Read moreA line the company does not file under the standard tag is left out rather than estimated.
Year toMar 2023Mar 2024
Diluted EPS54.1766.80
Basic EPS54.2866.93
Filing20-F20-F

INR per ordinary share, as filed.

Cash flow

Year toMar 2023Mar 2024
Cash from operations58,87545,433
Purchase of property, plant and equipment11,32316,403
Free cash flow47,55229,030
Cash from investing-41,373-40,283
Cash from financing-26,861-3,763
Depreciation and amortisation12,63614,841
Dividends paid4,9796,648
Filing20-F20-F

INR million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.

Balance sheet

Year toMar 2023Mar 2024
Funded by
Equity attributable to shareholders230,991280,550
Non-controlling interestsn/a0.0
Borrowings, as filed13,47220,020
Other liabilities77,39186,948
Total equity and liabilities321,854387,518
Owned
Property, plant and equipment66,46276,886
Goodwill4,2454,253
Other intangible assets30,84936,951
Cash and cash equivalents5,7797,107
Trade and other receivables72,48580,298
Inventories48,67063,552
Other assets93,364118,471
Total assets321,854387,518
Filing20-F20-F

INR million, at each fiscal year end.

Ratios on the filed lines

Year toMar 2023Mar 2024
Gross margin56.7%58.6%
Operating margin23.2%24.3%
Net margin18.3%19.9%
Free cash flow margin19.3%10.4%
Return on year-end equity19.5%19.8%
Effective tax rate25.3%22.5%
Filing20-F20-F

Arithmetic on the filed lines of the same year.

20-F for the year to 31 March 2024, filed 29 May 2026: the filing. The figures are in Indian rupees as filed.